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Nonalcoholic fatty liver disease (NAFLD) affects up
to 30% of the adult population in Western societies,
yet the underlying molecular pathways remain
poorly understood. Here, we identify the dimeric
Activator Protein 1 as a regulator of NAFLD. Fos-
related antigen 1 (Fra-1) and Fos-related antigen 2
(Fra-2) prevent dietary NAFLD by inhibiting prostea-
totic PPARg signaling. Moreover, established
NAFLD and the associated liver damage can be
efficiently reversed by hepatocyte-specific Fra-1
expression. In contrast, c-Fos promotes PPARg
expression, while c-Jun exerts opposing, dimer-
dependent functions. Interestingly, JunD was found
to be essential for PPARg signaling and NAFLD
development. This unique antagonistic regulation
of PPARg by distinct AP-1 dimers occurs at the
transcriptional level and establishes AP-1 as a link
between obesity, hepatic lipid metabolism, and
NAFLD.
INTRODUCTION
Given their high energy-to-weight ratio compared to carbohy-
drates and proteins, lipids are themost efficient energy substrate
in mammals. The adipose tissue is the major lipid storage
organ, and it is essential for controlling metabolic homeostasis
(Sethi and Vidal-Puig, 2007). In the healthy state, tissues such
as muscle and liver store only minor quantities of lipids (Lara-
Castro and Garvey, 2008). However, metabolic stress, as occur-
ring in obese or alcohol-abusing patients, can cause massive
ectopic lipid deposition, leading to a disease state termed
‘‘steatosis’’ or ‘‘fatty liver disease.’’ Depending on the etiology,
this disease can be further subgrouped into alcoholic or
nonalcoholic fatty liver disease (AFLD and NAFLD, respectively).
NAFLD is the most common liver disorder in industrialized
countries, and it frequently leads to severe liver inflammation
and damage, a disease state termed ‘‘nonalcoholic steatohepa-
titis’’ (NASH) (Browning and Horton, 2004). Moreover, NAFLD
contributes to hepatic insulin resistance in diabetes (Farese
et al., 2012) and is a risk factor for liver dysfunction and cancer84 Cell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc.development (Smedile and Bugianesi, 2005). Understanding
the cellular and molecular mechanisms leading to NAFLD, as
well as the identification of novel targets for NAFLD therapy,
has therefore become a priority (Cohen et al., 2011; Lazo and
Clark, 2008).
The Activator Protein 1 (AP-1) (Fos/Jun) protein complex is a
dimeric leucine zipper (bZIP) transcription factor. Three different
Jun proteins (c-Jun, JunB, and JunD) and four different Fos
proteins (c-Fos, FosB, Fra-1, and Fra-2) form AP-1 dimer. Jun
proteins can either form homodimers, such as c-Jun/c-Jun or
c-Jun/JunB, or heterodimers, such as c-Jun/c-Fos. In contrast,
Fos proteins exclusively form heterodimers (Halazonetis et al.,
1988). Jun and Fos proteins also form heterodimers with other
bZIP transcription factors, such as specific MAF and ATF family
members (Eferl and Wagner, 2003). Thus, a vast combinatorial
variety of AP-1 dimers with likely different molecular and biolog-
ical functions exists (Hess et al., 2004; Verde et al., 2007;Wagner
et al., 2010). Studies using genetically modifiedmice have unrav-
eled essential roles of AP-1-forming proteins in development,
inflammation, and cancer (Eferl and Wagner, 2003). Moreover,
AP-1 modulates the response to acute cellular insults, such as
oxidative stress and DNA damage (Shaulian and Karin, 2002).
Cellular stress typically activates AP-1 by augmenting transcrip-
tion, protein stability, and transactivation potential of Jun and
Fos family members (Wagner and Nebreda, 2009). In the liver,
the genetic inactivation of single Jun or Fos genes in hepatocytes
does not compromise organ homeostasis (Bakiri and Wagner,
2013; Eferl and Wagner, 2003). However, AP-1 is critical for the
liver’s response to acute stress. For example, c-Jun protects he-
patocytes from injury (Fuest et al., 2012; Hasselblatt et al., 2007)
and is essential for liver regeneration (Behrens et al., 2002) and
carcinogenesis (Eferl et al., 2003; Machida et al., 2010; Min
et al., 2012). More recently, we have documented that Fra-1,
but not Fra-2, protects hepatocytes from acetaminophen over-
dose, a paradigm for xenobiotic-mediated acute liver failure
(Hasenfuss et al., 2014). In contrast, little is known about the
role of AP-1 in chronic stress conditions and the potential contri-
bution of AP-1 to the development of hepatic metabolic disease.
Here we combined system genetics with gain- and loss-of-func-
tion mouse models to study the function of AP-1 in hepatic lipid
metabolism and NAFLD development. We show that, depending
on dimer composition, AP-1 either represses or activates the
transcription of the prosteatotic nuclear receptor Peroxisome
Proliferator-Activated Receptor g (PPARg), which promotes
hepatic lipid uptake and lipid droplet formation. Some AP-1
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Figure 1. Fra-1 Is Regulated by HFD and Inhibits NAFLD and PPARg Expression
(A) Hepatic fra-1 expression in CD and HFD (for 5 months; 60% kCal/fat) in 42 BXD inbred strains. Each data point represents the mean expression of five mice.
(B and C) Fra-1hep mice and control littermates were on CD or HFD (for 5–9months; 45% kCal/fat); nR 5/cohort. (B) Representative liver pictures and histology in
Fra-1hep and control mice; ORO, oil red O; bars, 1 cm and 100 mm. (C) Liver/body ratio, quantitation of ORO-positive areas, liver TG content, and serumALT levels.
Bar graphs are presented as mean ±SEM. See also Figure S1; Tables S2A and S2B.
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AP-1 Regulates PPARg Expression and NAFLDproteins, such as Fra-1 and Fra-2, inhibit the PPARg pathway
and reduce hepatic lipid content. In contrast, other AP-1 pro-
teins, such as c-Fos and JunD, induce hepatic PPARg signaling
and lipid accumulation. We also show that AP-1 regulates the
PPARg pathway through direct regulation of the Pparg2 pro-
moter. Using a mouse model for inducible hepatocyte-restricted
Fra-1 expression, we demonstrate that the Fra-1-induced sup-
pression of the PPARg pathway can revert established NAFLD.
For the first time, liver-specific single-chain JunFos forced
dimer mice were employed, in which dimerization of a Fos pro-
tein is restricted to a single Jun partner (Bakiri et al., 2002). The
analyses of these mouse models provide in vivo evidence that
distinct AP-1 dimers regulate the PPARg pathway in an antago-
nistic fashion. Finally, we show that JunD is essential for efficient
PPARg signaling and NAFLD formation. Overall, this study iden-
tifies AP-1 as a link between dietary obesity, hepatic lipid meta-
bolism, and NAFLD.
RESULTS
Fra-1/AP-1 Regulates Hepatic Lipid Metabolism and
NAFLD
To identify a possible function of AP-1 in metabolism, we
analyzed 42 genetically diverse mouse strains from the BXD
mouse genetic reference population (GRP) (Peirce et al., 2004).CTen animals for each strain were split evenly into two cohorts
fed chow diet (CD) or high-fat diet (HFD) for 5 months. Hepatic
AP-1 mRNA expression was then analyzed using genome-wide
expression profiles from the BXD strains. Fra-1 mRNA levels
were found to be significantly reduced in the HFD-fed cohort,
while the expression of c-fos, fosB, fra-2, c-jun, junb, and jund
were not affected by the diet (Figure 1A and see Figure S1A
online). To explore whether Fra-1 could causally contribute to
HFD-associated metabolic changes in the liver, we analyzed
hepatic metabolism in Fra-1hep mice, a previously established
model of Doxycycline (Dox)-controllable hepatocyte-restricted
Fra-1 overexpression, which does not display any obvious
phenotype under basal conditions (Hasenfuss et al., 2014) (for
details on mouse strains, see Table S1). After HFD feeding, the
livers appeared less pale on the macroscopic level and weighed
significantly less in Fra-1hep mice compared to HFD-fed litter-
mate controls (Figures 1B and 1C). Liver histology indicated
a reduction in lipid droplets in mutant mice (Figure 1B),
which was confirmed by the quantitation of oil red O (ORO)-pos-
itive lipid droplets and liver triglyceride (TG) content analysis
(Figure 1C).
We next addressed the effect of Fra-1 expression on NAFLD-
associated liver damage and inflammation. Augmented serum
levels of the liver damage marker alanine aminotransferase
(ALT) and increased hepatic inflammation marker expressionell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc. 85
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Figure 2. Fra-1 Regulates the PPARg Pathway
(A–D) Fra-1hep mice and control littermates on CD or HFD (for 5–9 months; 45% kCal/fat); n R 5 per condition. (A) (Top) Spearman correlation of R1.5-fold-
changed hepatic transcripts in Fra-1hep and control littermates (C57BL/6J) in CD (x axis) andHFD (y axis). (Bottom) Top common downregulated genes in Fra-1hep
livers. (B) KEGG pathway analyses for the top 2,000 most changed transcripts: PPAR target genes and their cellular functions are indicated. Transcripts changed
in CD, HFD, or both are highlighted in blue, red, and purple, respectively. Arrows indicate upregulation or downregulation. (C) qRT-PCR analyses of pparg and its
isoforms. (D) Immunoblot analyses in Fra-1hep and control mice. Vinculin served as loading control. Bar graphs are presented as mean ±SEM. See also Figure S2
and Table S3.
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AP-1 Regulates PPARg Expression and NAFLDwere observed in controls after HFD feeding, but not in Fra-1hep
mice (Figures 1C and S1B). Moreover, immunohistochemistry
(IHC) for the panlymphocyte marker CD45 and the macrophage
marker F4/80 revealed a significant reduction in immune cell in-
filtrates in HFD-fed mutants compared to diet-matched controls
(Figure S1C). In the HFD-fed state, serum IL-6 levels were also
reduced in HFD-fed Fra-1hep mice compared to controls (Table
S2A). We next explored the effects of hepatic Fra-1 expression
on circulating metabolite and hormone levels. Serum TG and
cholesterol were mildly elevated in HFD-fed Fra-1hep compared
to control mice in the fasted and/or fed states, while other serum
parameters were not affected (Tables S2A and S2B). Despite
decreased NAFLD and liver damage, glucose tolerance and
insulin tolerance tests (GTT and ITT) revealed that glucose
metabolism was not improved but rather slightly worsened in
HFD-fed mutants as compared to controls (Figure S1D). Similar
effects of Fra-1 on NAFLD development were also observed in
Fra-1hep mice on a C57BL/6J background or using 60% kCal/86 Cell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc.fat HFD (Table S2B and data not shown). These data collectively
suggest that hepatocyte-specific Fra-1 expression protects from
dietary-induced NAFLD and secondary liver damage and inflam-
mation but has little impact on systemic obesity and glucose
metabolism.
Fra-1 Represses the PPARg Pathway
We next analyzed the molecular mechanisms underlying
reduced NAFLD in Fra-1hep mice. Genome-wide hepatic gene
expression analyses in CD- and HFD-fed Fra-1hep mice demon-
strated that the expression of 3,000 genes was changed by at
least 1.5-fold in Fra-1hep livers. The vast majority of these genes
were regulated in a similar fashion in both dietary conditions, and
many PPARg targets, e.g., adipsin and cidea, were among the
top-downregulated genes (Figure 2A). KEGG pathway analysis
(Kanehisa et al., 2012) of the top 2,000 most changed genes
established PPARg signaling among the most significantly
affected pathways in both diet conditions (Figure 2B). A highly
Cell Metabolism
AP-1 Regulates PPARg Expression and NAFLDsignificant fraction of mRNAs, which were reduced in Fra-1hep
mice, were encoded by genes with promoters containing puta-
tive AP-1 sites (p = 9.0E-13) and PPARg response elements
(PPREs) (p = 3.3E-11), as revealed by UCSC TFBS conserved
tracks analyses (http://david.abcc.ncifcrf.gov/) (Huang et al.,
2009) (Table S3). qRT-PCR, immunoblot, and IHC analyses
confirmed decreased hepatic pparg mRNA/PPARg protein
expression in CD- and HFD-fed Fra-1hep mice (Figures 2C, 2D,
and S2A).
Decreased pparg mRNA levels were due to reduced expres-
sion of pparg2mRNA, themain pparg isoform in the liver (Figures
2C and S2D) (Lee et al., 2012). Among other metabolic regula-
tors, Nr0b2, a potential PPARg target (Kim et al., 2007) and
regulator (Kim et al., 2013), which encodes the orphan nuclear
receptor SHP, was also found reduced in HFD-fed Fra-1hep
mice (Figure S2C). Moreover, we confirmed reduced mRNA
expression for several PPARg target genes, such as fabp1 and
lpl, involved in hepatic lipid uptake, and plin2, cidea, fitm1,
fitm2, and g0s2, involved in lipid droplet formation (Figure S2E).
Notably, the Fra-1-induced reduction of ppary2 expression was
reversible, as pparg2 levels reverted to baseline levels upon
switching off the transgene (Figure S2F). Kinetic analyses of
another inducible Fra-1 mouse model (Fra-1tetON mice) (Hasen-
fuss et al., 2014) revealed that hepatic pparg2mRNA decreased
as early as 4 days after Fra-1 induction (Figure S2G).
Adenoviral PPARg Delivery Restores NAFLD/Steatosis
in Fra-1hep Mice
Gain- and loss-of-function studies previously established that
hepatocyte PPARg is both essential and sufficient for NAFLD
formation (Gavrilova et al., 2003; Lee et al., 2012; Matsusue
et al., 2003; Matsusue et al., 2008; Medina-Gomez et al., 2007;
Mora´n-Salvador et al., 2011). To determine whether reduced
NAFLD development in Fra-1hep mice is directly due to
decreased PPARg levels, HFD-fed Fra-1hep and control mice
were intravenously injected with either Adeno-PPARg or
Adeno-GFP control virus 8–10 days prior to sacrifice. Adeno-
PPARg did not have any obvious effect on liver macroscopy in
steatotic control mice (Figure 3A). In contrast, PPARg expression
increased ORO-positive lipid droplets, liver TG content, and
liver/body weight ratio in HFD-fed Fra-1hep mutant mice (Figures
3A and 3B). Moreover, Adeno-PPARg increased PPARg target
gene expression in the livers of Fra-1hep mice, as compared to
Adeno-GFP-treated mutants (Figures 3C and 3D). These data
demonstrate that the short-term induction of PPARg signaling
restores hepatic fat accumulation in HFD-fed Fra-1hepmice, sup-
porting its central function in the hepatic phenotype of Fra-1hep
mutant mice.
Reversion of NAFLD by Hepatocyte-Specific Fra-1
Expression
To examine whether Fra-1 induction in steatotic livers amelio-
rates disease symptoms, Fra-1hep and control littermates were
generated in the ‘‘Fra-1 off’’ state, and HFD-feeding was started
at 1 month of age (Figure 4A). As expected, control and mutant
mice were indistinguishable at 7 months of age in the absence
of transgene expression (Figures 4B–4D). Immunoblot analyses
confirmed comparable PPARg, Fsp27, and Fabp1 levels be-
tween control and mutant mice in the ‘‘Fra-1 off’’ state (Fig-Cure 4E). A cohort of Fra-1hep and control mice were kept on
HFD, but Fra-1 expression was switched on in mutant mice at
7 months of age (Fra-1 off-on). After 2 months of Fra-1 induction,
serum ALT was significantly lower in Fra-1hep mice than in con-
trol littermates and continued to improve 3 months later, while
the mice were maintained on HFD (Figure 4C). At this point the
liver was collected for macroscopy, histology, ORO-quantita-
tion, liver/body weight ratio, and liver TG content analysis,
revealing an almost complete reversion of NAFLD in Fra-1hep
mutants (Figures 4B–4D). Immunoblotting and qRT-PCR ana-
lyses confirmed transgene induction, as well as the repression
of PPARg, targets of PPARg, and inflammatory markers after
switching on Fra-1 expression (Figures 4E and 4F). These data
suggest that the Fra-1-mediated repression of the PPARg
pathway efficiently reversed established NAFLD and liver dam-
age in mice, even under continued stress of HFD feeding.
PPARg Links AP-1 to Lipid Metabolism
We next searched for correlations between AP-1 genes, PPARg,
and PPARg targets in gene expression arrays from the BXD
family of wild-type inbred mouse strains. This analysis revealed
that hepatic pparg expression, assessed with a probe detecting
both pparg isoforms, is significantly upregulated in HFD-fed
cohorts (Figure S3A). As expected, pparg mRNA levels strongly
correlated with the expression of PPARg targets, such as cidea
and adipsin (Figure S3B). Notably, and consistent with our find-
ings in Fra-1hep mice, a significant inverse correlation was found
between fra-1 and pparg and fra-1 and cidea regardless of the
diet (Figure 5A). Other PPARg targets, such as adipsin, followed
a similar trend without reaching statistical significance (Fig-
ure 5A). Interestingly, junb, a potential dimerization partner for
Fra-1, also negatively correlated with pparg (Figure 5B), indi-
cating that several AP-1 proteins consistently regulate PPARg
signaling in genetically diverse populations.
Antagonistic Regulation of Pparg2 by AP-1
The proximal promoter of the mouse Pparg2 gene (encoding
PPARg2), in which we identified several putative AP-1 sites (Fig-
ure 5C), is conserved across species (Figure S3D). Thus, we
assessed the binding of various Jun and Fos proteins to the
Pparg2 promoter. Chromatin samples were prepared from liver
tissue of mice deficient for individual AP-1 genes (Table S1)
and their respective littermates to control for antibody speci-
ficity. Chromatin immunoprecipitation (ChIP) assays revealed
that Fra-1, Fra-2, c-Fos, c-Jun, JunB, and JunD all efficiently
bound to the proximal Pparg2 promoter fragment in liver tissue
(Figure 5D). a-Flag ChIP assays also revealed a significant
enrichment for the same promoter fragment in livers from
Fra-1hep and c-Foshep mice (Figure S3E), a mouse model for
inducible c-Fos expression in the liver (Table S1). No enrichment
was observed for an unrelated genomic fragment in the same
a-Flag ChIP samples (Figure S3E). Fra-1, Fra-2, c-Fos, and Jun
proteins also bound to the human PPARG2 promoter, as
a-Fra-1, a-Fra-2, a-c-Fos, and a-pan-Jun ChIP samples, but
not control IgG ChIP samples, were enriched for the proximal
PPARG2 promoter region in human HuH7 hepatoma cells (Fig-
ure 5E). These data indicate that Jun and Fos proteins are func-
tionally involved in the direct regulation of the mouse Pparg2/
human PPARG2 promoter. We therefore analyzed the effectsell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc. 87
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Figure 3. PPARg Delivery Restores NAFLD Development in Fra-1hep Mice
(A–D) Fra-1hep and control littermates on HFD (for 4–5 months, 45% kCal/fat) were injected with Adenoviruses expressing PPARg (Ad-PPARg) or GFP (Ad-GFP)
8–10 days prior to sacrifice. n = 3 for control genotype/cohort; n = 4 for Fra-1hep mice/cohort. (A) Liver macroscopy and histology; bars, 1 cm and 100 mm.
(B) Quantitation of ORO-positive areas, liver/body ratio, and liver TG. (C) Immunoblot analyses in Fra-1hep and control mice. Vinculin served as loading control.
(D) qRT-PCR analyses of PPARg target genes involved in lipid uptake, lipogenesis, and lipid droplet formation; Ad-GFP controls are set to 1. Bar graphs are
presented as mean ±SEM.
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AP-1 Regulates PPARg Expression and NAFLDof Fos and Jun proteins on PPARG2 promoter activity. Reporter
assays revealed that the activity of a human PPARG2 luciferase
reporter was inhibited by transfecting Fra-1 and also by Fra-2 in
HuH7 and 293T cells (Figures 5F and S3F). In contrast, the
PPARG2 luciferase reporter was activated by c-Fos and in-
hibited by a dominant-negative Dc-Jun construct, which lacks
a transactivation domain (Figures 5F and S3F). Finally, PPARG2
reporter activation by c-Fos was efficiently inhibited by cotrans-88 Cell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc.fecting increasing amounts of Fra-2 (Figure 5G). These data
demonstrate that c-Fos and Fra-1/2 regulate the PPARG2 pro-
moter in an antagonistic manner.
AP-1 Dimer-Specific Regulation of PPARg Signaling
The consequences of hepatic c-Fos expression were analyzed in
c-Foshep mice. As early as 1 week after c-Fos induction, a strong
increase in ppary2 mRNA, PPARg protein, and PPARg target
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Figure 4. Fra-1 Expression Reverts NAFLD and Liver Damage
(A) Fra-1hep and control littermates were maintained in the ‘‘Fra-1 off’’ state, and HFD (45% kCal/fat) was supplied from 1 month of age. Mice were analyzed at
7 months (Fra-1 off, n = 2/cohort) or kept on HFD until 12 months, while transgene expression was induced (Fra-1 off-on, n = 6 per cohort).
(B) Liver macroscopy and histology; bars, 1 cm and 100 mm.
(C) Quantitation of ORO-positive areas and serum ALT.
(D) Liver/body ratio, and liver TG content.
(E) Immunoblot analyses in Fra-1hep and control mice. Vinculin served as loading control.
(F) qRT-PCR analyses of fra-1, pparg isoforms, PPARg target genes, and inflammation markers (Fra-1 off-on). Bar graphs are presented as mean ± SEM.
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AP-1 Regulates PPARg Expression and NAFLDgene expression was observed in c-Foshep mice, while ppary1
was only mildly affected and nr0b2 unchanged (Figures 6A,
6B, S4A, and S4B). After switching off transgene expression,
c-fos, ppary2, and PPARg target genes reverted to baseline
levels (on-off, Figure 6A). The reversible induction of ppary2
expression was confirmed in c-Foshep mice after 8 weeks of
transgene induction (Figure S4B). Next, we studied the effect
of Junc-Fos forced dimers (Bakiri et al., 2002) on hepatic
PPARg signaling using transgenic mice, in which dimerization
of c-Fos is restricted to c-Jun, JunB, or JunD (Table S1). The
expression of all Junc-Fos dimers, such as c-Junc-Fos,CJunBc-Fos, and JunDc-Fos, increased ppary2 mRNA and
PPARg target gene expression in the livers of mutant mice,
with c-Junc-Fos causing the strongest induction (Figure 6C).
As the expression of c-Fos or Junc-Fos forced dimers rapidly
caused lethal liver dysplasia (data not shown), the long-term
consequences of increased PPARg signaling on lipid meta-
bolism and NAFLD could not be further investigated.
We next explored the effect of Fra-2 and Fra-2/AP-1 dimers on
PPARg signaling and hepatic lipid metabolism. In contrast to
c-Fos and Junc-Fos dimers, hepatocyte-restricted Fra-2
monomer expression in Fra-2hep mice inhibited the PPARgell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc. 89
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Figure 5. Several AP-1 Proteins Regulate
the PPARg Pathway
(A and B) Correlation plots for fra-1 with pparg,
cidea, and adipsin (A) and for Jun members with
pparg (B) in CD and HFD (5 months; 60% kCal/fat)
in the BXD inbred family. Each data point repre-
sents the average expression from five pooled
mice. Pearson’s r was used to analyze correla-
tions, and p values are indicated.
(C) Proximal murine Pparg2 promoter: position of
the putative AP-1 binding TPA-responsive element
(TRE) is indicated relative to the transcription start.
The ChIP-PCR amplicon is depicted in red.
(D) ChIP assays using hepatic chromatin from
AP-1-deficient mice. Endpoint PCR products
representative of three independent experiments
are shown.
(E) ChIP assays in Huh7 cells; primers amplifying a
region homologous to (C) were used. Data are
representative of three independent experiments.
(F and G) Human PPARG2 reporter assays in
HuH7 cells. Data are mean ± SEM of four inde-
pendent experiments in (F). Technical replicates of
one representative experiment (n = 2) are shown,
and ectopic c-Fos and Fra-2 expression is
confirmed by immunoblot in (G). RLU, relative
luminescence units. DJun, truncated c-Jun. Con-
trol (empty vector) is set to 1. Bar graphs are pre-
sented as mean ±SEM. See also Figure S3.
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AP-1 Regulates PPARg Expression and NAFLDpathway and prevented NAFLD development (Figures S4C–
S4G). c-JunFra-2-forced dimers in c-JunFra-2hep mice sup-
pressed PPARg signaling and NAFLD development to a similar
extent as Fra-2 monomers (Figures 6D, 6E, and S4H–S4J). In
contrast to most established PPARg target genes, nr0b2
levels were unaffected in Fra-2hep mice (Figure S4G), while a
mild upregulation of nr0b2 mRNA was observed in CD-fed
c-JunFra-2hep mice (Figure S4J). These data collectively sug-
gest an antagonistic regulation of the PPARg pathway and lipid
metabolism by c-Fos/AP-1 and Fra-2/AP-1 dimers in vivo.
JunD Is Essential for NAFLD Development
To investigate whether individual Jun or Fosmembers are essen-
tial for hepatic PPARg expression and lipid metabolism, we
employed loss-of-function mutant mice. Individual gene inacti-
vation of Fra-1, Fra-2, or c-Fos had no effect on hepatic pparg2
expression, nor on HFD-induced NAFLD (Figure S5A; data not
shown). Similarly, the single inactivation of c-Jun or Junb did90 Cell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc.not affect hepatic pparg2 expression
(Figure S5A), while JunD/ mice dis-
played decreased pparg2 levels in the
liver under basal conditions (Figure S5A).
We therefore analyzed HFD-induced
NAFLD development in JunD-deficient
mice. Liver macroscopy, histology, liver
TG content analyses, and ORO quantita-
tion revealed decreased HFD-induced
NAFLD in JunD/ livers (Figures 7A and
7B). qRT-PCR, immunoblot, and IHC
analysis confirmed decreased pparg2
mRNA/PPARg protein levels in HFD-fedJunD/mice compared to controls in both diet conditions (Fig-
ures 7C and S5B). qRT-PCR analyses revealed reduced expres-
sion of the PPARg targets cidea and fitm1 in JunD/ livers,
whereas nr0b2 expression was not affected (Figure S5C).
As previously reported (The´pot et al., 2000), JunD/mice had
a reduced body weight, and this effect was maintained in HFD
(Figure 7B). Total liver and fat pad weights were specifically
decreased after HFD feeding in JunD/mice compared to litter-
mate controls (Figure 7B; Table S4). Interestingly, reduced
pparg2 mRNA was also observed in heart tissue of HFD-fed
JunD/mice (Figure S5D), indicating that AP-1might also regu-
late the PPARg pathway in other organs.
DISCUSSION
Combined forward and reverse genetic approaches have a
strong potential for discovering new regulators of metabolism.
The initial identification of Fra-1 as a potential obesity-related
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Figure 6. Antagonistic Regulation of PPARg Signaling by AP-1
(A) qRT-PCR analyses of c-fos (endogenous+ectopic), pparg1/2, and PPARg targets in c-Foshep and control mice. c-Fos expression was induced for 1 week
(c-Fos on) or induced for 1 week and switched off for 1 week (c-Fos on-off). n = 8 for c-Foshep mice (on), n = 10 for controls (on), n = 3 for c-Foshep (on-off).
(B) Immunoblot analyses in c-Foshep (c-Fos on for 1 week) and control mice. Vinculin served as a loading control. Blots are representative of three controls and
four mutants.
(C–E) (C) qRT-PCR analyses in JunBc-Foshep (n = 6), JunDc-Foshep (n = 5), and c-Junc-Foshep(n = 4) (transgene on for 1 month) and control (n = 5) mice. Liver
macroscopy and histology (D) and immunoblot analyses (E) of c-JunFra-2hepmice (c-JunFra-2 switched on at 1month) and control littermates onCDorHFD (for
4months; 60%kCal/fat). Vinculin servedas loading control; bars, 1 cmand50mm;nR5per condition.Bargraphsarepresentedasmean±SEM.SeealsoFigureS4.
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AP-1 Regulates PPARg Expression and NAFLDgene in livers from the BXD population of inbred mouse strains
prompted us to further explore the role of AP-1 proteins. Subse-
quent mechanistic studies led to the discovery that AP-1 can
function as a molecular link between obesity and liver meta-
bolism. First, this study established AP-1 as a potent regulator
of lipid metabolism and NAFLD development. Second, gene
pathway analysis and BXD population genetics highlighted the
AP-1 complex as a regulator of hepatic PPARg signaling. Third,
we demonstrate that Fra-1 repressed the PPARg-dependent
expression of genes involved in lipid uptake/lipid droplet forma-
tion and thereby efficiently improved established steatosis, liverCdamage, and inflammation. Fourth and maybe most intriguingly,
themousePparg2 and the humanPPARG2 promoter were found
to be regulated in an antagonistic fashion by distinct AP-1 dimers
(Figure 7D).
PPARg promotes lipid uptake by increasing the expression of
lipid transporters, such as fatty acid binding proteins (Fabps),
and by promoting lipid storage in lipid droplets. Lipid droplet
proteins (LDPs) inhibit TG lipolysis, thereby preventing lipid-
droplet breakdown (Fujimoto et al., 2008; Puri et al., 2008;
Sun et al., 2012). Several LDPs are regulated by PPARg at
the transcriptional level (reviewed in Tontonoz and Spiegelman,ell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc. 91
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Expression and Steatosis Formation
(A–C) Analyses of JunD/ and JunD+/ control
littermates (males and females) on CD or HFD (for
9 months; 45% kCal/fat); n R 7 per condition. (A)
Representative liver macroscopy and histology;
bars, 1 cm and 100 mm. (B) Macroscopic param-
eters, liver TG content, and quantitation of ORO-
positive areas; relative levels are plotted and
sex-matched controls set to 1. Bar graphs are
presented as mean ±SEM. (C) Immunoblot anal-
ysis for PPARg and Vinculin.
(D) Antagonistic regulation of PPARg expression
by different AP-1 dimers: c-Fos induces PPARg as
a dimer with any Jun protein, while Fra-1 and Fra-2
repress PPARg, likely by dimerizing with c-Jun,
thereby affecting hepatic lipid metabolism and
NAFLD. See also Figure S5 and Table S4.
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AP-1 Regulates PPARg Expression and NAFLD2008) and promote NAFLD in mice, including Cidea, Plin2,
and Fsp27 (Chang et al., 2006; Dalen et al., 2004; Matsusue
et al., 2008; Sun et al., 2012; Varela et al., 2008; Zhou et al.,
2012). Similarly, deletion of the fatty acid transporter Fabp1
reduced the dietary induction of NAFLD (Newberry et al.,
2003, 2006). Previous studies suggested that hepatic PPARg
also promotes hepatic lipogenesis (Matsusue et al., 2003;
Medina-Gomez et al., 2007). In Fra-1hep mice, which display a
dramatic reduction in PPARg levels, decreased expression of
the Stearoyl-CoA desaturase-1 (SCD-1), a key enzyme in the
generation of unsaturated fatty acids, was observed. However,
no consistent changes in the expression of SREBP-1/2, the
main transcriptional regulators of de novo lipogenesis, or in
the SREBP-1/2 targets FAS and ACC were observed. Since
FAS and ACC catalyze the rate-limiting steps in fatty acid syn-
thesis, altered lipogenesis likely does not play a major role in
the Fra-1-mediated repression of NAFLD. Instead, decreased
hepatic lipid uptake and lipid droplet formation are most likely
the primary cause for reduced steatosis formation in Fra-1hep,
Fra-2hep, and c-JunFra-2hep mice. Previous reports have
shown that PPARg induced the expression of Nr0b2 (Kim
et al., 2007). In line with this, HFD-fed Fra-1hep mice displayed
reduced pparg2 and nr0b2 levels, which appeared normalized
after Adeno-PPARg treatment. More recently, Nrob2 was
shown to be required for hepatic PPARg expression and
NAFLD (Kim et al., 2013). However, we did not observe a
consistent correlation between pparg2 and nr0b2 expression
across dietary conditions in our AP-1 mutant mouse models.
Therefore, AP-1 likely regulates pparg2 and NAFLD indepen-
dently of Nr0b2.92 Cell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc.Hepatocyte-specific Pparg deletion,
like Fra-1 overexpression, has been
shown to reduce liver TG and to increase
serum TG levels in the obese ob/ob mice
and the AZIP lipodystrophy model, likely
due to decreased hepatic lipid uptake
(Gavrilova et al., 2003; Matsusue et al.,
2003). Moreover, PPARg2-dependent
hepatic steatosis has been suggested
to buffer systemic TG levels (Medina-Gomez et al., 2007). Similar to mice with hepatocyte-restricted
Pparg deletion, Fra-1hep mice displayed worsened glucose
metabolism after HFD feeding, despite a reduction in NAFLD.
Thus, hepatic Fra-1 overexpression largely phenocopies the
effects of hepatocyte-specific Pparg deletion on lipid and
glucose metabolism. As elevated serum TG levels are associ-
ated with diabetes development, increased serum TG levels
likely contribute to the deterioration of glucose metabolism in
HFD-fed Fra-1hep and Pparg-deficient mice.
Our data suggest a functional antagonism between activating
c-Fos/AP-1 and repressing Fra/AP-1 dimers. Interestingly,
c-Jun/c-Fos dimers increased, whereas c-Jun/Fra-2 dimers
reduced, PPARg2 expression, suggesting a partner-dependent
effect of c-Jun on Pparg2 promoter activity. Previous studies in
other organs suggested overlapping functions of c-Fos and
Fra-1/2 (Fleischmann et al., 2000; Matsuo et al., 2000). Thus,
we here identify Pparg as the first gene to be antagonistically
regulated by different Fos proteins. This finding raises the
intriguing question, how do structurally similar protein com-
plexes, such as c-Fos/AP-1 and Fra/AP-1 dimers, have opposite
effects on the same promoter?While further research is required
to address this question, several AP-1 corepressors, such as
Sirt1 (Purushotham et al., 2009) and HDAC3 (Feng et al., 2011;
Knutson et al., 2008; Sun et al., 2012), are involved in hepatic
lipid metabolism.We speculate that specifically Fra/AP-1 dimers
might interact with such corepressors to inhibit Pparg2 promoter
activity.
Among Jun proteins, JunD was found to be important for
NAFLD development in the liver. As JunD/ mice are leaner
and display reduced adiposity, the possibility that extrahepatic
Cell Metabolism
AP-1 Regulates PPARg Expression and NAFLDfunctions of JunD contribute to decreased NAFLD development
in JunD/mice cannot be excluded. However, JunD is essential
for normal pparg2mRNA/PPARg protein expression and bound
to the Pparg2 promoter in liver tissue, suggesting JunD as a
physiologically relevant regulator of hepatic PPARg signaling.
Given the key function of PPARg in NAFLD development,
reduced PPARg signaling in the liver likely contributes to NAFLD
resistance in JunD/ mice.
The described data from gain- and loss-of-function mouse
models, together with the correlations between AP-1 compo-
nents and the PPARg pathway in the BXD cohort, establish
AP-1 as an important regulator of PPARg signaling and NAFLD.
HFD affects a plethora of cellular signaling cascades, such as the
Insulin (Kim and Kahn, 1994), the JNK (Hibi et al., 1993), and the
PKC (Boyle et al., 1991) pathways. As these pathways are also
known regulators of AP-1 expression and activity, exploring
how they affect AP-1 levels and dimerization during obesity is
certainly an important challenge for future experiments. More-
over, extensive crosstalk between AP-1 and transcription factors
of the NF-kB (Fujioka et al., 2004) and the nuclear receptor family
(Glass and Saijo, 2010; Ricote and Glass, 2007; Wan et al., 2007)
has been described. Future studies should reveal the molecular
interplay of these pathways with AP-1 signaling in the context of
NAFLD in both mice and human.
EXPERIMENTAL PROCEDURES
Animal Procedures
Mice were maintained in a 12 hr light/12 hr dark cycle with food and water ad
libitum. Chow (D8604, Harlan), 45% kCal/fat HFD (D12451, Research Diets)
and 60% kCal/fat HFD (D12492, Research Diets), was used as specified in
the figure legends. If not indicated otherwise, male mice were used, and
HFD feeding was started between 4 and 8 weeks of age. Dox (1 g/l) was
supplied in sucrose-containing (100 g/l) drinking water. The BXD mice were
sacrificed after overnight fasting, while in other experiments the mice
were sacrificed in CO2 chambers between 2 and 5 p.m. in the fed state.
Fasted cholesterol and TG measurements were performed using serum from
overnight fasted mice. For intraperitoneal GTT and ITT tests, mice were fasted
for 6 hr (GTT) or 8 hr (ITT) and intraperitoneally injected with 1 mg glucose/kg
body weight (GTT) or 0,5 U insulin/kg body weight (ITT). Glucose and insulin
were diluted in PBS to an injectable volume. Blood glucose was determined
by tail puncture for all time points. All mouse experiments were performed in
accordance with local and institutional regulations. Details on mouse strains
can be found in Table S1.
Blood Analyses
Blood was collected from the submandibular vein, by tail puncture or by
cardiac puncture at experimental endpoints. Unless otherwise specified,
parameters were analyzed in the fed state. Serum ALT, TG, and cholesterol
levels were determined using a Reflovet blood chemistry analyzer and
glucose using an Accucheck glucose analyzer (Aviva). Serum leptin, resistin,
adiponectin, and IL-6 were measured using Quantikine ELISA kits (R&D),
and serum insulin was determined with an ultrasensitive ELISA (Mercodia).
Serum b-HB and FFA were measured using enzymatic assays (Cayman
Chemicals).
qRT-PCR/Immunoblot Analysis
qRT-PCR was performed using the GoTaq qPCR Master Mix and an Eppen-
dorf light cycler. Expression levels were calculated using the DCt-method.
Data were normalized to a housekeeping gene (rps27 or rpl0). Primer
sequences are available upon request. Immunoblot analysis was performed
using standard protocols and following antibodies: ACC, PPARg, CEBPb,
c-Jun, phospho-CREBP, total CREB (Cell Signaling), Vinculin (Sigma), PPARg,
Parp-1, CEBPa, c-Fos, Fra-1 (Santa Cruz), HNF4, FAS, Fabp1 (Abcam), Fsp27C(Novus Biologicals), and SREBP-1/2 (BD Bioscience). Nuclear extracts from
liver tissue were obtained using the NE-PER Nuclear Protein Extraction Kit
(Pierce).
Histology
H&E and ORO staining were performed using standard procedures. ORO-
positive areas were quantified as previously described (Mehlem et al.,
2013). IHC was performed as described (Hasenfuss et al., 2014) using the
following antibodies: PPARg (Cell Signaling), CD45 (Abcam), and F4/80 (AbD
Serotec).
RNA Microarray
RNA was isolated using the RNEasy Midi Kit (QIAGEN), and RNA integrity was
evaluated using an Agilent 2100 Bioanalyzer. Samples of RNA integrity score
above 7.8 were used for microarray analysis. A total of 100 ng of RNA was
labeled with Cy3 (RNA pool from at least five control mice, which were either
fed CD or HFD) or Cy5 (RNA samples from individual mutants, which
were either fed CD or HFD) using the Low Input Quick Amp Labeling Kit
Version 6.5 (Agilent). Labeled RNAs were purified using RNeasy spin columns
(QIAGEN) and hybridized to a mouse gene expression array G3 8x60K (Agilent
microarray design ID 028005, P/N G4852A). On each array, the Cy3-labeled
control pool and one Cy5 labeled mutant sample were hybridized at
65C for 17 hr. The microarray was scanned on a 2505C DNA microarray
scanner (Agilent), and images were analyzed using the Feature Extraction
Software Version 10.7 (Agilent). Multiple testing correction was performed
using the Benjamin-Hochberg procedure. Data are deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO Series acces-
sion number GSE52275 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE52275). Hepatic gene expression of the BXD strains was analyzed
using Mouse Gene 1.0 ST Arrays (Affymetrix) and are accessible on http://
www.genenetwork.org. Standard array analysis methods were used, e.g.,
RMA normalization, as described elsewhere (Irizarry et al., 2003).
Gene Pathway Analysis
Microarray data were analyzed separately in CD and HFD conditions by
comparing control to mutant livers. All nominally significant changes with
fold changeR1.5 were retained. Gene sets were then winnowed using multi-
ple testing correction (Benjamin-Hochberg) and entered independently into
Web Gestalt (http://bioinfo.vanderbilt.edu/webgestalt/). Enriched pathways
were generated based on KEGG gene ontology annotations. The PPARg
signaling pathway was found significantly modulated in both dietary condi-
tions. The two independently generated pathways were then overlaid and
redrawn to generate the pathway diagram.
Cell Culture and Reporter Assay
HuH7 and 293T cells were cultured in DMEM/10%FCS at 37C and 5% CO2.
For reporter assays, 0.8 3 105 HuH7 or 293T cells were plated per well of
a 24-well plate. Twenty-four hours later, 0.01 mg Renilla vector, 0.2 mg
PPARG2-luc vector (Saladin et al., 1999), and 0.6 mg pCMV-AP-1 or pCMV-
empty control vector were transfected using Lipofectamine 2000 (Invitrogen).
Cells were harvested 48 hr after transfection, and luciferase activity was
analyzed using the Dual-Glo Luciferase Assay (Promega).
Liver TG Content Analysis
Frozen liver tissue (25–75 mg) was homogenized in chloroform/methanol
(8:1 v/v; 500 ml per 25 mg tissue) and shaken at RT for 8–16 hr. H2SO4 was
added to a final concentration of 0.28 M. After centrifugation, the lower phase
was collected and dried, and TG content was measured using an enzymatic
assay (Caymen Chem).
Chromatin Immunoprecipitation
ChIP was performed using the following antibodies: Flag (F3165, Sigma), Fra-1
(SC-183, Santa Cruz), Fra-2 (rat, CNIO polyclonal), c-Fos (PC-05, Calbio-
chem), c-Jun (BD), JunB (SC-73, Santa Cruz), and JunD (CS5000, Cell
Signaling). Pan Jun ChIP with HuH7 cells has been performed with a mixture
of two antibodies raised against an epitope present in all Jun proteins. For de-
tails on the ChIP protocol, see also Supplemental Experimental Procedures.ell Metabolism 19, 84–95, January 7, 2014 ª2014 Elsevier Inc. 93
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Statistical significance was calculated using Student’s two-tailed t test if not
indicated otherwise: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
For procedure details, see Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supplemental
Experimental Procedures and can be found with this article at http://dx.doi.
org/10.1016/j.cmet.2013.11.018.
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